vs
Side-by-side financial comparison of Chemours Co (CC) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $346.4M, roughly 3.8× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs -3.5%, a 31.6% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -2.1%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $92.0M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CC vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $346.4M |
| Net Profit | $-47.0M | $97.3M |
| Gross Margin | 11.7% | 57.2% |
| Operating Margin | — | 36.1% |
| Net Margin | -3.5% | 28.1% |
| Revenue YoY | -2.1% | 4.8% |
| Net Profit YoY | -261.5% | — |
| EPS (diluted) | $-0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $1.3B | $339.0M | ||
| Q3 25 | $1.5B | $327.3M | ||
| Q2 25 | $1.6B | $321.4M | ||
| Q1 25 | $1.4B | $330.6M | ||
| Q4 24 | $1.4B | $348.5M | ||
| Q3 24 | $1.5B | $345.5M | ||
| Q2 24 | $1.6B | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $-47.0M | $44.7M | ||
| Q3 25 | $46.0M | $38.7M | ||
| Q2 25 | $-380.0M | $34.0M | ||
| Q1 25 | $-5.0M | $58.0M | ||
| Q4 24 | $-13.0M | $37.5M | ||
| Q3 24 | $-32.0M | $33.8M | ||
| Q2 24 | $60.0M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 11.7% | 59.7% | ||
| Q3 25 | 15.6% | 59.5% | ||
| Q2 25 | 17.2% | 59.8% | ||
| Q1 25 | 17.3% | 58.4% | ||
| Q4 24 | 19.4% | 55.5% | ||
| Q3 24 | 19.0% | 54.2% | ||
| Q2 24 | 19.8% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | 2.5% | 17.9% | ||
| Q2 25 | -15.4% | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | -0.1% | 16.9% | ||
| Q3 24 | -2.1% | 15.0% | ||
| Q2 24 | 4.4% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | -3.5% | 13.2% | ||
| Q3 25 | 3.1% | 11.8% | ||
| Q2 25 | -23.5% | 10.6% | ||
| Q1 25 | -0.4% | 17.5% | ||
| Q4 24 | -1.0% | 10.8% | ||
| Q3 24 | -2.1% | 9.8% | ||
| Q2 24 | 3.9% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.32 | $0.95 | ||
| Q3 25 | $0.31 | $0.81 | ||
| Q2 25 | $-2.53 | $0.70 | ||
| Q1 25 | $-0.03 | $1.17 | ||
| Q4 24 | $-0.07 | $0.74 | ||
| Q3 24 | $-0.22 | $0.66 | ||
| Q2 24 | $0.39 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | $245.4M |
| Total DebtLower is stronger | $4.1B | $1.2B |
| Stockholders' EquityBook value | $250.0M | $796.3M |
| Total Assets | $7.4B | $2.4B |
| Debt / EquityLower = less leverage | 16.40× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $670.0M | $363.4M | ||
| Q3 25 | $613.0M | $296.4M | ||
| Q2 25 | $502.0M | $292.9M | ||
| Q1 25 | $464.0M | $306.8M | ||
| Q4 24 | $713.0M | $320.8M | ||
| Q3 24 | $596.0M | $299.3M | ||
| Q2 24 | $604.0M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $4.1B | $1.2B | ||
| Q3 25 | $4.1B | $1.2B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $4.1B | $1.2B | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $250.0M | $911.5M | ||
| Q3 25 | $274.0M | $849.2M | ||
| Q2 25 | $228.0M | $882.3M | ||
| Q1 25 | $566.0M | $820.8M | ||
| Q4 24 | $571.0M | $906.9M | ||
| Q3 24 | $643.0M | $878.9M | ||
| Q2 24 | $714.0M | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $7.4B | $2.5B | ||
| Q3 25 | $7.5B | $2.4B | ||
| Q2 25 | $7.5B | $2.5B | ||
| Q1 25 | $7.4B | $2.5B | ||
| Q4 24 | $7.5B | $2.5B | ||
| Q3 24 | $7.5B | $2.5B | ||
| Q2 24 | $7.2B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 16.40× | 1.34× | ||
| Q3 25 | 14.96× | 1.44× | ||
| Q2 25 | 17.99× | 1.39× | ||
| Q1 25 | 7.18× | 1.49× | ||
| Q4 24 | 7.11× | — | ||
| Q3 24 | 6.20× | — | ||
| Q2 24 | 5.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $293.2M |
| Free Cash FlowOCF − Capex | $92.0M | $209.9M |
| FCF MarginFCF / Revenue | 6.9% | 60.6% |
| Capex IntensityCapex / Revenue | 3.4% | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $137.0M | $93.6M | ||
| Q3 25 | $146.0M | $111.3M | ||
| Q2 25 | $93.0M | $17.4M | ||
| Q1 25 | $-112.0M | $116.6M | ||
| Q4 24 | $138.0M | $43.8M | ||
| Q3 24 | $139.0M | $48.8M | ||
| Q2 24 | $-620.0M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $92.0M | $87.2M | ||
| Q3 25 | $105.0M | $106.3M | ||
| Q2 25 | $50.0M | $13.6M | ||
| Q1 25 | $-196.0M | $100.9M | ||
| Q4 24 | $29.0M | $35.2M | ||
| Q3 24 | $63.0M | $39.4M | ||
| Q2 24 | $-693.0M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 6.9% | 25.7% | ||
| Q3 25 | 7.0% | 32.5% | ||
| Q2 25 | 3.1% | 4.2% | ||
| Q1 25 | -14.3% | 30.5% | ||
| Q4 24 | 2.1% | 10.1% | ||
| Q3 24 | 4.2% | 11.4% | ||
| Q2 24 | -44.6% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 3.4% | 1.9% | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 2.7% | 1.2% | ||
| Q1 25 | 6.1% | 4.7% | ||
| Q4 24 | 8.0% | 2.5% | ||
| Q3 24 | 5.0% | 2.7% | ||
| Q2 24 | 4.7% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | 3.17× | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | -10.33× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
